Asset
Daraxonrasib
Revolution Medicines Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06625320 | phase3 | active_not_recruiting | 2024-10-16 | 2026-06-01 | Revolution Medicines, Inc. | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT06881784 | phase3 | recruiting | 2025-05-06 | 2027-12-01 | Revolution Medicines, Inc. | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) |
| NCT07252232 | phase3 | recruiting | 2025-12-15 | 2029-05-10 | Revolution Medicines, Inc. | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07491445 | phase3 | recruiting | 2026-03-09 | 2028-06-01 | Revolution Medicines, Inc. | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
| NCT06128551 | phase1_2 | recruiting | 2023-11-14 | 2028-12-01 | Revolution Medicines, Inc. | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 220910 | NDA | REVOLUTION MEDICINES INC |
Marketed products (2)
- RASONQUE
- RASONQUE